Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study
IP therapy improves OS in LUAD patients with LM, particularly offering significant benefit as salvage treatment for those with ECOG 3-4. Proteomic analysis suggests plasma MCP-2 and CSF ARG1 are promising predictive biomarkers for IP response. The small sample size in biomarker analysis may limit these findings, necessitating validation through multicenter studies.
Authors
- Ruiguang Zhang
- Lingjuan Chen (ORCID: https://orcid.org/0000-0003-2463-0640)
- Hongxia Zhou (ORCID: https://orcid.org/0000-0001-9206-2580)
- Xiaorong Dong (ORCID: https://orcid.org/0000-0001-7470-1836)
- Zhi Wang (ORCID: https://orcid.org/0000-0002-5276-1413)
- Xing Zhang (ORCID: https://orcid.org/0000-0001-8542-8353)
- Yaqin Liu (ORCID: https://orcid.org/0000-0002-6982-1849)
- Peng Ding (ORCID: https://orcid.org/0009-0006-4426-7833)
- Fan Tong (ORCID: https://orcid.org/0000-0002-4588-8520)
- Bo‐Hua Kuang
- Minghui Ge
Institutions
- Union Hospital (HK)
- Simcere Pharmaceutical (China) (CN)
- Wuhan Union Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1093/oncolo/oyaf291
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China